Danaher Corporation

Valuation Analysis

About the Company

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale

Danaher Corporation Stock at a Glance

Danaher Corporation (DHR) is currently trading at $180.10 with a market capitalization of $127.5B. The trailing P/E ratio stands at 34.84x, with a forward P/E of 19.49x. The 52-week range spans from $160.93 to $242.80; the current price is 25.8% below the yearly high. Year-over-year revenue growth stands at +3.7%. The net profit margin stands at 14.89%.

💰 Dividend

Danaher Corporation pays an annual dividend of $1.60 per share, representing a yield of 0.89%. The payout ratio stands at 26.36%.

📊 Analyst Rating

23 analysts rate Danaher Corporation (DHR) on consensus: Strong Buy. The average price target is $242.35, implying +34.56% from the current price. Analyst price targets range from $200.00 to $310.00.

Danaher Corporation: The Investment Case in Detail

Danaher Corporation (DHR) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

The combination of a 58.99% gross margin and 22.94% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Strong Buy with an average price target implying roughly 34.56% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue growth has slowed to just 3.7%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The PEG ratio at 1.15 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 19.49x is meaningfully below the trailing 34.84x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 34.56% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Danaher Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.